Identification of VKORC1 interaction partners by split-ubiquitin system and coimmunoprecipitation

Summary

Since the discovery of vitamin K epoxide reductase complex subunit 1 (VKORC1), the key enzyme for the regeneration of vitamin KH2, numerous studies have addressed the role of VKORC1 in the posttranslational modification of vitamin K-dependent proteins. VKORC1 is also the target protein of anticoagulant drugs of the coumarin type (e.g. warfarin). Genetic variants in VKORC1 have recently been shown to significantly affect the coumarin dose and international normalised ratio level. In the present study, we have used the split-ubiquitin yeast two-hybrid system to identify potential interaction partners of VKORC1. With this system we could identify 90 candidates. Out of these, we focused on VKORC1 itself, its paralog VKORC1L1, emopamil binding protein (EBP) and stress-associated endoplasmic reticulum protein 1 (SERP1). By coimmunprecipitation and colocalisation experiments, we were able to demonstrate evidence for the interaction of these proteins. Mutations in the EBP gene cause X-linked dominant chondrodysplasia punctata (CDPX2) which can be considered as a phenocopy of warfarin embryo-pathy. The interaction could be a link between these phenotypes. SERP1 represents an oxidative stress-associated endoplasmatic reticulum protein with chaperon-like functions. Antioxidant capacities have been described for vitamin K hydroquinone, the substrate of VKORC1. Both VKORC1 and SERP1, might have a synergistic function in eliminating reactive oxygen species generated during the VKOR redox process. Further studies are needed to investigate the role of these proteins in the vitamin K pathway.

Keywords

VKOR - EBP - chondrodysplasia punctata - warfarin embryopathy - SERP1

• References

• 1 Benzakour O. Vitamin K-dependent proteins: Functions in blood coagulation and beyond. Thromb Haemost 2008; 100: 527-529.
• 2 Fregin A, Rost S, Wolz W. et al. Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K – dependent clotting factors to the centromeric region of chromosome 16. Blood 2002; 100: 3229-3232.
• 3 Oldenburg J, von Brederlow B, Fregin A. et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 2000; 84: 937-941.
• 4 Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 2008; 100: 530-547.
• 5 Hauschka P, Lian J, Cole D. et al. Osteocalcin and Matrix Gla Protein: Vitamin K-Dependent Proteins in Bone. Physiol Rev 1989; 69: 990-1047.
• 6 Weitz J. New oral anticoagulants in development. Thromb Haemost 2010; 103: 62-70.
• 7 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-541.
• 8 Wilms EB, Touw DJ, Conemans JMH. et al. A new VKORC1 allelic variant (p. Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon. J Thromb Haemost 2008; 6: 1224-1226.
• 9 Pelz H-J, Rost S, Hünerberg M. et al. The genetic basis of resistance to anticoagulants in rodents. Genetics 2005; 170: 1839-1847.
• 10 Menger H, Lin AE, Toriello HV. et al. Vitamin K Deficiency Embryopathy: A Phenocopy of the Warfarin Embryopathy Due to a Disorder of Embryonic Vitamin K Metabolism. Am J Med Genet 1997; 72: 129-134.
• 11 Watzka M, Geisen C, Bevans CG. et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insight into improved patient diagnosis and treatment. J Thromb Haemost. 2010 Epub ahead of print.
• 12 Spohn G, Kleinridders A, Wunderlich F. et al. VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding. Thromb Haemost 2009; 101: 1044-1050.
• 13 Watzka M, Westhofen P, Hass M. et al. Polymorphisms in VKORC1 and GGCX are not major genetic determinants of vitamin K-dependent coagulation factor activity in Western Germans. Thromb Haemost 2009; 102: 418-420.
• 14 Klein T, Altman R, Eriksson N. et al. with International Warfarin Pharmacogenetics Consortium. Estimation of the Warfarin Dose with Clinical and Pharmaco-genetic Data. N Engl J Med 2009; 360: 753-764.
• 15 Geisen C, Watzka M, Sittinger K. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-779.
• 16 Oldenburg J, Bevans CG, Fregin A. et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-576.
• 17 Goodstadt L, Ponting CP. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci 2004; 29: 289-292.
• 18 Li W, Schulman S, Dutton RJ. et al. Structure of a bacterial homologue of vitamin K epoxide reductase. Nature 2010; 463: 507-512.
• 19 Schulman S, Wang B, Li W. et al. Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners. Proc Natl Acad Sci USA 2010; 107: 15027-15032.
• 20 Cain D, Hutson SM, Wallin R. Assembly of the Warfarin-sensitive Vitamin K 2,3-Epoxide Reductase Enzyme Complex in the Endoplasmic Reticulum Membrane. J Biol Chem 1997; 272: 29068-29075.
• 21 Cain D, Hutson SM, Wallin R. Warfarin Resistance Is Associated with a Protein Component of the Vitamin K 2,3-Epoxide Reductase Enzyme Complex in Rat Liver. Thromb Haemost 1998; 80: 128-133.
• 22 Wallin R, Hutson SM, Cain D. et al. A molecular mechanism for genetic warfarin resistance in the rat. FASEB J 2001; 15: 2542-2544.
• 23 Wajih N, Sane DC, Hutson SM. et al. The Inhibitory Effect of Calumenin on the Vitamin K-dependent gamma-Carboxylation System. J Biol Chem 2004; 279: 25276-25283.
• 24 Chu P-H, Huang T-Y, Williams J. et al. Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH 2. Proc Natl Acad Sci USA 2006; 103: 19308-19313.
• 25 Wajih N, Hutson SM, Wallin R. Disulfide-dependent Protein Folding Is Linked to Operation of the Vitamin K Cycle in the Endoplasmic Reticulum. J Biol Chem 2007; 282: 2626-2635.
• 26 Rost S, Pelz H-J, Menzel S. et al. Novel mutations in the VKORC1 gene of wild rats and mice – a response to 50 years of selection pressure by warfarin?. BMC Genet 2009; 610: 4.
• 27 Stagljar I, Korostensky C, Johnsson N. et al. A genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins. Proc Natl Acad Sci USA 1998; 95: 5187-5192.
• 28 Kittanakom S, Chuk M, Wong V. et al. Analysis of Membrane Protein Complexes Using the Split-Ubiquitin Membrane Yeast Two-Hybrid (MYTH) System. Methods Mol Biol 2009; 548: 247-271.
• 29 Wadelius M, Chen LY, Eriksson N. et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23-34.
• 30 Moebius FF, Fitzky BU, Wietzorrek G. et al. Cloning of an emopamil-binding protein (EBP)-like protein that lacks sterol delta 8 – delta 7 isomerase activity. Biochem J 2003; 237: 229-237.
• 31 Okiyama K, Smith DH, Thomas MJ. et al. Evaluation of a novel calcium channel blocker, (S)-emopamil, on regional cerebral edema and neurobehavioral function after experimental brain injury. J Neurosurg 1992; 77: 607-615.
• 32 Yamaguchi A, Hori O, Stern DM. et al. Stress-associated Endoplasmic Reticulum Protein 1 (SERP1)/Ribosome-associated Membrane Protein 4 (RAMP4) Stabilizes Membrane Proteins during Stress and Facilitates Subsequent Glycosylation. Cell 1999; 147: 1195-1204.
• 33 Silve S, Dupuy PH, Labit-Lebouteiller C. et al. Emopamil-binding Protein, a Mammalian Protein That Binds a Series of Structurally Diverse Neuroprotective Agents, Exhibits delta8-delta7 Sterol Isomerase Activity in Yeast. J Biol Chem 1996; 271: 22434-22440.
• 34 Hori O, Miyazaki M, Tamatani T, Ozawa K, Takano K, Okabe M. et al. Deletion of SERP1/RAMP4, a Component of the Endoplasmic Reticulum (ER) Translocation Sites, Leads to ER Stress. Mol Cell Biol. 2006; 26: 4257-4267.
• 35 Chien C-T, Bartel PL, Sternglanz R. et al. The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest. Proc Natl Acad Sci USA 1991; 88: 9578-9582.
• 36 Gross E, Kastner DB, Kaiser CA. et al. Structure of Ero1p, Source of Disulfide Bonds for Oxidative Protein Folding in the Cell. Cell 2004; 117: 601-610.
• 37 Tu BP, Weissman JS, Francisco S. The FAD- and O 2 -Dependent Reaction Cycle of Ero1-Mediated Oxidative Protein Folding in the Endoplasmic Reticulum. Mol Cell 2002; 10: 983-994.
• 38 Chakravarthi S, Jessop CE, Bulleid NJ. The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress. EMBO Rep 2006; 7: 1-5.
• 39 Mukai K, Morimoto H, Kikuchi S. et al. Kinetic study of free-radical-scavenging action of biological hydroquinones (reduced forms of ubiquinone, vitamin K and tocopherol quinone) in solution. Biochim Biophys Acta 1993; 1157: 313-317.
• 40 Mukai K, Itoh S, Morimoto H. Stopped-flow Kinetic Study of Vitamin E Regeneration Reaction with Biological Hydroquinones (Reduced Forms of Ubiquinone, Vitamin K, and Tocopherolquinone) in Solution. J Biol Chem 1992; 267: 22277-22281.
• 41 Vervoort LM, Ronden JE, Thijssen HH. The Potent Antioxidant Activity of the Vitamin K Cycle in Microsomal Lipid Peroxidation. Biochem Pharmacol 1997; 54: 871-876.
• 42 Li J, Lin JC, Wang H. et al. Novel Role of Vitamin K in Preventing Oxidative Injury to Developing Oligodendrocytes and Neurons. J Neurosci 2003; 23: 5816-5826.
• 43 Braverman N, Lin P, Moebius FF. et al. Mutations in the gene encoding 3 beta-hydroxysteroid-delta 8, delta 7-isomerase cause X-linked dominant Conradi-Hünermann syndrome. Nat Genet 1999; 22: 291-294.
• 44 Hello M, David A, Barbarot S. Conradi-Hünermann-Happle syndrome with uni-lateral distribution. Ann Dermatol Venereol 2010; 137: 44-47.
• 45 Hall JG, Pauli RM, Wilson KM. Maternal and Fetal Sequelae of Anticoagulation During Pregnancy. Am J Med 1980; 68: 122-140.
• 46 Pauli RM, Lian JB, Mosher DF. et al. Association of Congenital Deficiency of Multiple Vitamin K-dependent Coagulation Factors and the Phenotype of the Warfarin Embryopathy: Clues to the Mechanism of Teratogenicity of Coumarin Derivatives. Am J Hum Genet 1987; 41: 566-583.
• 47 Cozzolino M. Matrix-Gla protein and vascular calcification: the negative role of oral anticoagulant therapy. Thromb Haemost 2009; 101: 605-606.
• 48 Cranenburg ECM, Schurgers LJ, Vermeer C. Vitamin K: The coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98: 120-125.
• 49 Smadja DM, Loriot M, Hindorff LA. et al. No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease. Thromb Haemost 2008; 99: 970-972.
• 50 Soute BAM, Spronk HMH, Mutucumarana VP. et al. Characteristics of recombinant W501S mutated human gamma-glutamyl carboxylase. J Thromb Haemost 2004; 2: 597-604.